Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKSE: 1349) is trading at HK$2.61, about ₹32 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, down 0.57% today. Indian residents can buy Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$2.57
Today's high
HK$2.61
52 week low
HK$2.20
52 week high
HK$3.69
1349 opened at HK$2.60, closed previously at HK$2.63, and has traded between HK$2.20 and HK$3.69 over the past 52 weeks.
About
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., along with its affiliated entities, is dedicated to the research, development, production, and commercialization of biopharmaceutical products. The company leverages its genetic engineering platform to advance antibody-drug conjugates (ADCs), including CD30-DM1 ADC and Trop2-SN38 ADC, both in Phase I clinical trials for various tumors. Trop2-BB05 ADC is undergoing preclinical evaluation for lung and triple-negative breast cancers, while HER2 ADC has completed preclinical studies for metastatic breast and gastric cancers. Furthermore, Fudan-Zhangjiang utilizes its photodynamic technology platform, featuring hemoporfin in Phase IV clinical trials for port-wine stains, and aminolevulinic acid, which is progressing through Phase II trials for HPV-related cervical conditions and acne, having also finished preclinical investigation for brain gliomas. Its nanotechnology platform is advancing drugs like Nanoparticle Albumin-bound Paclitaxel, undergoing preclinical assessment for oncological applications, and Doxorubicin liposome, also under development for tumors. The firm's expertise in oral solid preparations encompasses obeticholic acid for hepatobiliary and autoimmune disorders; timolol maleate cream, currently in preclinical studies for infantile hemangioma; and the oral formulation FZJ-003, which is in Phase I clinical trials for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond pharmaceuticals, the company is involved in developing both pharmaceutical and medical devices, as well as medical diagnostic solutions and associated services. It also markets everyday consumer goods, clinical laboratory analysis equipment, and relevant software. Additional activities include technology innovation, licensing, consultancy, and promotional efforts, alongside the manufacturing of lyophilized powder injections and active pharmaceutical ingredients (APIs). The company also allocates capital to international medical ventures. Established in 1996, the company operates from its headquarters in Shanghai, People's Republic of China.
Key statistics
Avg. volume
2.22M
Market cap
HK$887.40M
P/E Ratio
-69.72
Price-to-sales ratio
1.44
Enterprise value
-CN¥250.32M
Free cash flow yield
14.89%
Debt-to-equity ratio
0.01
Return on equity
-5.84%
ROIC
-6.56%
Beta
0.09
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥685.80M
Earnings per share
-CN¥0.14
Free cash flow
CN¥110.19M
Net profit margin
-18.90%
Gross margin
99.50%
EBITDA
-CN¥81.53M
Revenue growth
-3.33%
Similar securities
This is not an investment recommendation
How to buy Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India
Indian residents can buy Shanghai Fudan-Zhangjiang Bio-Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and place an order
Find Shanghai Fudan-Zhangjiang Bio-Pharmaceutical by name or by its ticker, 1349, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Shanghai Fudan-Zhangjiang Bio-Pharmaceutical position in HKD and INR. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India
Trading and taxes when buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneShanghai Fudan-Zhangjiang Bio-Pharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Shanghai Fudan-Zhangjiang Bio-Pharmaceutical stock?
Yes. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (1349) has been listed on the Hong Kong Stock Exchange since 2002, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Shanghai Fudan-Zhangjiang Bio-Pharmaceutical share cost in rupees?
One Shanghai Fudan-Zhangjiang Bio-Pharmaceutical share is HK$2.61 — about ₹32 at an HKD/INR rate of 12.23 on 26 Sep 2026. Both the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical price. Paasa issues a capital-gains statement for your return.
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical pay a dividend?
No. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Shanghai Fudan-Zhangjiang Bio-Pharmaceutical from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical a Hong Kong SAR China company, and does that change how it is taxed?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Shanghai Fudan-Zhangjiang Bio-Pharmaceutical holding, its cost and its closing value.
How do I sell Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.